to-BBB awarded EUR 1.25 million European FP7 funding to develop treatments for inherited retinal diseases
The consortium aims to develop drugs and drug delivery systems for the treatment of inherited photoreceptor degeneration up to the clinical stage. These orphan diseases often display a dysregulated cGMP metabolism or signaling, which could be counteracted by cyclic nucleotide analogues. The German Small Medium Enterprise (SME) Biolog is specialized in the development of cyclic nucleotide based drugs, and to-BBB will focus on the targeted delivery of these compounds across the blood-retinal barrier, a barrier with similar characteristics as the blood-brain barrier. The three research institutes from Germany, Italy and Sweden have a long-standing record of studying photoreceptor degenerative mechanisms and testing and evaluating of drug treatment effects.
The project has started on September 1st, with a duration of 3 years ending August 31st, 2015. The consortium will have its kick-off meeting later this week to officially launch the project and start its activities.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.